Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4105-4112

  Loehrer Sr , Patrick J ^a   Feng, Yang ^b   Cardenes, Higinia ^a   Wagner, Lynne ^c   Brell, Joanna M ^d   Cella, David ^c   Flynn, Patrick ^e   Ramanathan, Ramesh K ^g   Crane, Christopher H ^h   Alberts, Steven R ^f   Benson III, Al B ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Minneapolis Hematology/Oncology   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; HEMOGLOBIN;

ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ANOREXIA; APNEA; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; COLITIS; CONTROLLED STUDY; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; EDEMA; EMBOLISM; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; LEUKOCYTE; LUNG COMPLICATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MELENA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE; THROMBOSIS; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80755143456     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.8904     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al.: Cancer Statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Niederhuber JE, Brennan MF, Menck HR: The National Cancer Data Base report on pancreatic cancer. Cancer 76:1671-1677, 1995
3. Klaassen DJ, MacIntyre JM, Catton GE, et al.: Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - An Eastern Cooperative Oncology Group study. J Clin Oncol 3:373-378, 1985 (Pubitemid 15132005)
4. Crane CH, Abbruzzese JL, Evans DB, et al.: Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52:1293-1302, 2002 (Pubitemid 34302881)
5. Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592-1599, 2008
6. Burris HA III, Moore MJ, Anderson J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997 (Pubitemid 27251144)
7. Brade A, Brierley J, Oza A, et al.: Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study. Int J Radiat Oncol Biol Phys 67:1027-1036, 2007
8. Okusaka T, Ito Y, Ueno H, et al.: Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 91:673-677, 2004 (Pubitemid 39141622)
9. Kornek GV, Potter R, Selzer E, et al.: Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys 49:665-671, 2001 (Pubitemid 32112194)
10. Ikeda M, Okada S, Tokuuye K, et al.: A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86:1551-1554, 2002 (Pubitemid 34628107)
11. Blackstock AW, Bernard SA, Richards F, et al.: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17:2208-2212, 1999 (Pubitemid 29318854)
12. Wolfe RA, Evans DB, Gravel DM, et al.: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7:2246-2253, 2001 (Pubitemid 32751621)
13. McGinn CJ, Zalupski MM, Shureiqi I, et al.: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208, 2001 (Pubitemid 33081637)
14. Epelbaum R, Rosenblatt E, Nasrallah S, et al.: Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81:138-143, 2002 (Pubitemid 35253625)
15. Goldstein D, Van Hazel G, Walpole E, et al.: Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 97:464-471, 2007 (Pubitemid 47258454)
16. de Lange SM, van Groeningen CJ, Meijer OW, et al.: Gemcitabine- radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 38:1212-1217, 2002 (Pubitemid 34603482)
17. Cardenes HR, Moore AM, Johnson CS, et al.: A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer: A Hoosier Oncology Group study. Am J Clin Oncol [epub ahead of print on September 24, 2010]
18. Heffernan N, Cella D, Webster K, et al.: Measuring health-related quality of life in patients with hepatobiliary cancers: The Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. J Clin Oncol 20:2229-2239, 2002 (Pubitemid 34441650)
19. Jennison C, Turnbull BW: Group sequential analysis incorporating covariate information. J Am Stat Assoc 92:1330-1341, 1997
20. Lawrence TS, Chang EY, Hahn TM, et al.: Radiosensitization of pancreatic cancer cells by 2′, 2′difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867-872, 1996
21. Mishra G, Butler J, Ho C, et al.: Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28:345-350, 2005 (Pubitemid 41099538)
22. Allen AM, Zalupski MM, Robertson JM, et al.: Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 59:1461-1467, 2004 (Pubitemid 38954069)
23. Murphy JD, Adusumilli S, Griffith KA, et al.: Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801-808, 2007 (Pubitemid 46818734)
24. McGinn CJ, Smith DC, Szarka CE, et al.: A phase I study of gemcitabine in combination with radiation therapy in patients with localized unresectable pancreatic cancer. Proc Am Soc Clin Oncol 17:10145, 1998
25. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 (Pubitemid 46972777)
26. Wilkowski R, Thoma M, Schauer R, et al.: Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 28:1011-1018, 2004 (Pubitemid 40109886)
27. Maurel J, Martin-Richard M, Conill C, et al.: Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-H gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 66:1391-1398, 2006
28. Duffy A, Kortmansky J, Schwartz GK, et al.: A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced nonoperable pancreatic adenocarcinoma. Ann Oncol 19:86-91, 2008
29. Muler JH, McGinn CJ, Normolle D, et al.: Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 22:238-243, 2004 (Pubitemid 41095087)
30. Philip PA, Zalupski MM, Vaitkevicius VK, et al.: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92:569-577, 2001 (Pubitemid 32735192)
31. Talamonti MS, Catalano PJ, Vaughn DJ, et al.: Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 18:3384-3389, 2000
32. Ko AH, Quivey JM, Venook AP, et al.: A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68:809-816, 2007 (Pubitemid 46818742)
33. Symon Z, Davis M, McGinn CJ, et al.: Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: From the laboratory to the clinic. Int J Radiat Oncol Biol Phys 53:140-145, 2002 (Pubitemid 34465817)
34. Murphy JD, Adusumilli S, Griffith KA, et al.: Full dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Rad Oncol Phys 68:801-808, 2007 (Pubitemid 46818734)
35. Huguet F, André T, Hammel P, et al.: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J Clin Oncol 25:326-331, 2007 (Pubitemid 350003022)
36. Kindler H, Niedzwiecki D, Hollis DR, et al.: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patient (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Presented at the 2007 Gastrointestinal Cancers Symposium, Orlando, FL, January 19-21, 2007 (abstr 108)
37. Poplin E, Feng Y, Berlin J, et al.: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778-3785, 2009
38. Rich T, Harris J, Abrams R, et al.: Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27:51-56, 2004 (Pubitemid 38176292)
39. Rich T, Myerson R, Harris J, et al.: A randomized phase II trial of weekly gemcitabine (G), paclitaxel (P), and external irradiation followed by the farnesyl transferase inhibitor R115777 (NSC#702818) for locally advanced pancreatic cancer (RTOG 0020). Presented at the 2006 Gastrointestinal Cancers Symposium, January 26-28, 2006, San Francisco, CA (abstr 121)